XML 35 R23.htm IDEA: XBRL DOCUMENT
v3.24.4

Acquisition of Nora Pharma Inc. (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] |
Schedule of allocation of purchase price |
Schedule of allocation of purchase price |  |  |  |
Accounts receivable |  | $ | 1,358,121 |
Inventory |  |  | 3,181,916 |
Intangible assets |  |  | 659,571 |
Equipment & furniture |  |  | 210,503 |
Other assets |  |  | 1,105,093 |
Total assets |  |  | 6,515,204 |
Liabilities assumed |  |  | (5,981,286 | )
Net assets |  |  | 533,918 |
Goodwill |  |  | 18,326,719 |
Total Consideration |  | $ | 18,860,637 |

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationAndAssetAcquisitionAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration